How does it work?
ACTISORB™ Silver 220 is different from other charcoal dressings, it has a triple
action that not only masks odour but also addresses its cause.
To learn more about the triple action click here.
ACTISORB™ Silver 220 is effective against 150 microorganisms associated with wound infection, including MRSA and VRE3-5.
A recent study shows the dressing provides effective antimicrobial action without causing any harm to host cells nor preventing fibroblast proliferation6,7.
Odour and exudate management
ACTISORB™ Silver 220 eliminates malodour thereby improving the patient’s quality of life4,5,8,9.
As malodour might be accompanied by wound fluids, ACTISORB™ Silver 220 is able to manage exudate and helps maintain a moist wound healing environment8,10.
C1677 Nov 2013
1. Nisbet, L. et al. The benefits of activated charcoal cloth with silver on odour control and bacterial endotoxin binding. Poster, Wounds UK 2011 (in vitro).
2. Addison, D. et al. A comparison of the antimicrobial properties of silver dressings for chronic wound care. Poster, EWMA 2002 (in vitro).
3. Rennison et al. Antimicrobial efficacy of silver impregnated activated charcoal wound dressing. Poster, ETRS 2003.
4. Jackson, L. Use of a charcoal dressing with silver on an MRSA-infected wound. B J Comm nursing 2001, Vol. 2:19-26.
5. Leak, K. PEG site infections: a novel use for Actisorb Silver 220. B J Comm Nursing 2002, Vol. 7(6):321-325.
6. Cullen, B. The effects of silver-based wound dressings on protease activity and cell proliferation. Poster, 2003.
7. Nisbet, L. et al. The beneficial effects of a non-releasing silver containing wound dressings on fibroblast proliferation. Poster, Wounds UK 2011.
8. Hampton, S., Actisorb Silver 220: a unique antibacterial dressing. J Comm Nursing 2002:17-19.
9. Leak, K. Changing wound care practice: management of percutaneous endoscopic gastrostomy sites. Case Studies. 2003.
10. Warrick, J. et al. Clinical efficacy of a silver impregnated activated charcoal wound dressing. Poster, WOCN 2003.
11. International case series: Using ACTISORB™: Case Studies. London: Wounds International, 2012.
C1677 Nov 2013